FIELD: medicine.
SUBSTANCE: group of inventions relates to treatment of neurological disorders. Proposed: liquid composition for treatment of a neurological disorder such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, parkinson-like syndrome, progressive supranuclear palsy (PSP), multiple systemic atrophy (MSA) or amyotrophic lateral sclerosis (ALS) in joint therapy with levodopa, moreover, this composition contains from 0.5 to 20 wt.% arginine, from 0.5 to 6 wt.% carbidopa, from 0 to 30 wt.% N-methylpyrrolidone (NMP), from 0 to 5 wt.% polyvinylpyrrolidone (PVP) and from 0 to 5 wt.% one or more water-soluble antioxidants, has a pH from about 8.0 to about 9.5 and is essentially stable at 25 °C for 48 hours or more, and a kit of the same purpose comprising said composition for continuous administration and a second composition for oral administration containing a therapeutically effective amount of levodopa or its salt and instructions.
EFFECT: increase in the level of levodopa in the brain after the administration of the kit and the stability of the proposed solution of arginine and carbidopa.
12 cl, 12 dwg, 6 tbl, 16 ex
